Abstract
Diffuse large B cell lymphoma (DLBCL) comprises specific subtypes, disease entities, and other not otherwise specified (NOS) lymphomas. This review will focus on DLBCL NOS because of their prevalence and their heterogeneity with respect to morphology, clinical presentation, biology, and response to treatment. Gene expression profiling of DLBCL NOS has identified molecular subgroups that correlate with prognosis and may have relevance for treatment based on signaling pathways. New technologies have revealed that the "activated B cell" subgroup is linked to activation of the nuclear factor kB (NF-kB) pathway, with mutations found in CD79A/B, CARD11, and MYD88, and loss of function mutations in TNFAIP3. The "germinal center B cell-like" subgroup is linked to mutational changes in EZH2 and CREBBP. Biomarkers that are related to pathways promoting tumor cell growth and survival in DLBCL have been recognized, although their predictive role requires clinical validation. Immunohistochemistry for detecting the expression of these biomarkers is a practical technique that could provide a rational for clinical trial design.
| Original language | English |
|---|---|
| Pages (from-to) | 1263-1277 |
| Number of pages | 15 |
| Journal | Annals of Hematology |
| Volume | 93 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Biomarkers
- Diagnosis
- DLBCL
- Prognosis
- Treatment
ASJC Scopus subject areas
- Hematology
Cite this
Diffuse large B cell lymphoma : Using pathologic and molecular biomarkers to define subgroups for novel therapy. / Carbone, Antonino; Gloghini, Annunziata; Kwong, Yok Lam; Younes, Anas.
In: Annals of Hematology, Vol. 93, No. 8, 2014, p. 1263-1277.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Diffuse large B cell lymphoma
T2 - Using pathologic and molecular biomarkers to define subgroups for novel therapy
AU - Carbone, Antonino
AU - Gloghini, Annunziata
AU - Kwong, Yok Lam
AU - Younes, Anas
PY - 2014
Y1 - 2014
N2 - Diffuse large B cell lymphoma (DLBCL) comprises specific subtypes, disease entities, and other not otherwise specified (NOS) lymphomas. This review will focus on DLBCL NOS because of their prevalence and their heterogeneity with respect to morphology, clinical presentation, biology, and response to treatment. Gene expression profiling of DLBCL NOS has identified molecular subgroups that correlate with prognosis and may have relevance for treatment based on signaling pathways. New technologies have revealed that the "activated B cell" subgroup is linked to activation of the nuclear factor kB (NF-kB) pathway, with mutations found in CD79A/B, CARD11, and MYD88, and loss of function mutations in TNFAIP3. The "germinal center B cell-like" subgroup is linked to mutational changes in EZH2 and CREBBP. Biomarkers that are related to pathways promoting tumor cell growth and survival in DLBCL have been recognized, although their predictive role requires clinical validation. Immunohistochemistry for detecting the expression of these biomarkers is a practical technique that could provide a rational for clinical trial design.
AB - Diffuse large B cell lymphoma (DLBCL) comprises specific subtypes, disease entities, and other not otherwise specified (NOS) lymphomas. This review will focus on DLBCL NOS because of their prevalence and their heterogeneity with respect to morphology, clinical presentation, biology, and response to treatment. Gene expression profiling of DLBCL NOS has identified molecular subgroups that correlate with prognosis and may have relevance for treatment based on signaling pathways. New technologies have revealed that the "activated B cell" subgroup is linked to activation of the nuclear factor kB (NF-kB) pathway, with mutations found in CD79A/B, CARD11, and MYD88, and loss of function mutations in TNFAIP3. The "germinal center B cell-like" subgroup is linked to mutational changes in EZH2 and CREBBP. Biomarkers that are related to pathways promoting tumor cell growth and survival in DLBCL have been recognized, although their predictive role requires clinical validation. Immunohistochemistry for detecting the expression of these biomarkers is a practical technique that could provide a rational for clinical trial design.
KW - Biomarkers
KW - Diagnosis
KW - DLBCL
KW - Prognosis
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84904743618&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904743618&partnerID=8YFLogxK
U2 - 10.1007/s00277-014-2116-y
DO - 10.1007/s00277-014-2116-y
M3 - Article
C2 - 24870942
AN - SCOPUS:84904743618
VL - 93
SP - 1263
EP - 1277
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
IS - 8
ER -